Applications including "InertSustain C8"

LT206 - Anaysis of Antioxidant capacity by pre-column HPLC using DPPH radical -

LC Technical Note InertSustainSwift C8
LT205 - Anaysis of stable radical DPPH -

LC Technical Note InertSustainSwift C8
LT200 - InertSustain & Inertsil HPLC Columns for Reversed Phase Separation -

LC Technical Note InertSustain C18 InertSustain AQ-C18 InertSustainSwift C18 InertSustain AX-C18 Inertsil ODS-HL Inertsil ODS-4 Inertsil ODS-3 Inertsil ODS-P Inertsil ODS-EP InertSustain C8 Inertsil C8-4 Inertsil C4 Inertsil WP300 C18 Inertsil WP300 C8 Inertsil WP300 C4 InertSustain PFP InertSustain Phenyl InertSustain Phenylhexyl
LB094 - Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB900 - Analysis of Fesoterodine Fumarate -

LC InertSearch InertSustain C8
LB895 - Analysis of Venlafaxine hydrochloride -

LC InertSearch InertSustainSwift C8
LB856 - Analysis of Lithium lactylate -

LC InertSearch InertSustain C8
LB706 - Analysis of Per - and Polyfluoroalkyl Substances (PFAS) -

LC InertSearch InertSustain AQ-C18
LB705 - Analysis of Per - and Polyfluoroalkyl Substances (PFAS) -

LC InertSearch InertSustain AQ-C18
LB672 - Analysis of Stearyl Glycyrrhetinate -

LC InertSearch InertSustainSwift C8
LB637 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Extended-Release Tablets) -

LC InertSearch InertSustain C8
LB619 - Analysis of Venlafaxine hydrochloride (Under the Condition of USP41-NF36, Venlafaxine Hydrochloride) -

LC InertSearch InertSustain C8
LB617 - Analysis of Levocetirizine -

LC InertSearch Inertsil SIL-100A
LT130 - Analysis of Anion Surfactants by LC/MS/MS -

LC Technical Note InertSustain C18 HP Inertsil C8-4 HP
LT108 - Simultaneous Analysis of Organic Fluorine Compounds Using LC/MS/MS -

LC Technical Note InertSustain C18
LT100 - Inertsil HPLC Columns for Reversed Phase Separation (2) -

LC Technical Note InertSustain C18 Inertsil ODS-4 Inertsil ODS-3 Inertsil ODS-2 Inertsil ODS-SP Inertsil ODS-EP Inertsil ODS-P Inertsil WP300 C18 InertSustain C8 Inertsil C8-3 Inertsil C8-4 Inertsil WP300 C8 InertSustain Phenyl Inertsil Ph-3 Inertsil Ph
LB535 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustainSwift C8
LB534 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustain C8
LB483 - Analysis of Minocycline Hydrochloride (Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustainSwift C8
LB472 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C8
LB471 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB468 - Analysis of Vitamin K（InertSustainSwift C8） -

LC InertSearch InertSustainSwift C8
LB463 - Analysis of Ibuprofen (Under the Condition of USP 39-NF34, Ibuprofen Oral Suspension) -

LC InertSearch InertSustain C8
LB448 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 3-Aminophenol, 3-Aminobenzoic acid, Gentisic acid, Salicylic acid, other related substances and total related substance) -

LC InertSearch InertSustain C8
LB282 - Analysis of Povidone (Under the Condition of the Japanese Pharmacopoeia 16th edition, (4) 1-Vinyl-2-pyrrolidone) -

LC InertSearch InertSustain C8
LB262 - Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustain C8
LB195 - Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB193 - Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB191 - Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB189 - Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB148 - Analysis of Cyanocobalamin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB124 - Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB123 - Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB093 - Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB056 - Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB055 - Analysis of Olopatadine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB054 - Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB044 - Analysis of Pyridine derivatives (InertSustain C8) -

LC InertSearch InertSustain C8
LB040 - Analysis of Phospholipids (InertSustain C8) -

LC InertSearch InertSustain C8
LB030 - Analysis of Vitamin K (InertSustain C8) -

LC InertSearch InertSustain C8
LB020 - Analysis of Losartan Potassium and Hydrochlorothiazide -

LC InertSearch InertSustain C8

Applications including "InertSustain C8"

LT206 - Anaysis of Antioxidant capacity by pre-column HPLC using DPPH radical -

LT205 - Anaysis of stable radical DPPH -

LT200 - InertSustain & Inertsil HPLC Columns for Reversed Phase Separation -

LB094 - Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LB900 - Analysis of Fesoterodine Fumarate -

LB895 - Analysis of Venlafaxine hydrochloride -

LB856 - Analysis of Lithium lactylate -

LB706 - Analysis of Per - and Polyfluoroalkyl Substances (PFAS) -

LB705 - Analysis of Per - and Polyfluoroalkyl Substances (PFAS) -

LB672 - Analysis of Stearyl Glycyrrhetinate -

LB637 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Extended-Release Tablets) -

LB619 - Analysis of Venlafaxine hydrochloride (Under the Condition of USP41-NF36, Venlafaxine Hydrochloride) -

LB617 - Analysis of Levocetirizine -

LT130 - Analysis of Anion Surfactants by LC/MS/MS -

LT108 - Simultaneous Analysis of Organic Fluorine Compounds Using LC/MS/MS -

LT100 - Inertsil HPLC Columns for Reversed Phase Separation (2) -

LB535 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LB534 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LB483 - Analysis of Minocycline Hydrochloride (Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LB472 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB471 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB468 - Analysis of Vitamin K（InertSustainSwift C8） -

LB463 - Analysis of Ibuprofen (Under the Condition of USP 39-NF34, Ibuprofen Oral Suspension) -

LB448 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 3-Aminophenol, 3-Aminobenzoic acid, Gentisic acid, Salicylic acid, other related substances and total related substance) -

LB282 - Analysis of Povidone (Under the Condition of the Japanese Pharmacopoeia 16th edition, (4) 1-Vinyl-2-pyrrolidone) -

LB262 - Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) -

LB195 - Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LB193 - Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LB191 - Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LB189 - Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LB148 - Analysis of Cyanocobalamin (Under the Condition of the Japanese Pharmacopoeia) -

LB124 - Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) -

LB123 - Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) -

LB093 - Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LB056 - Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) -

LB055 - Analysis of Olopatadine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) -

LB054 - Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia) -

LB044 - Analysis of Pyridine derivatives (InertSustain C8) -

LB040 - Analysis of Phospholipids (InertSustain C8) -

LB030 - Analysis of Vitamin K (InertSustain C8) -

LB020 - Analysis of Losartan Potassium and Hydrochlorothiazide -

Application Search